An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2010-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A clinical study to assess if a new investigational drug is effective in treating malignant mesothelioma, compared to a chemotherapy treatment (Navelbine®). In this study the patients will be assigned by chance to receive either the new drug or a chemotherapy treatment (Navelbine®). Treatment will continue as long as the cancer does not worsen and the patient wishes to continue in the study. The study will recruit approximately 66 patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Vinorelbine in Mesothelioma

NCT02139904

Mesothelioma

COMPLETED PHASE2

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

NCT00410761

Thyroid Cancer

COMPLETED PHASE3

Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

NCT00509041

Malignant Mesothelioma

COMPLETED PHASE2

Phase II Study of Vandetanib in Individuals With Kidney Cancer

NCT00566995

Renal Cancer Von Hippel Lindau

COMPLETED PHASE2

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

NCT00309946

Advanced Malignant Mesothelioma Epithelial Mesothelioma Localized Malignant Mesothelioma +2 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mesothelioma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Vinorelbine

Group Type ACTIVE_COMPARATOR

Vinorelbine

Intervention Type DRUG

2

Vandetanib

Group Type EXPERIMENTAL

Vandetanib

Intervention Type DRUG

once daily oral dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vinorelbine

Intervention Type DRUG

Vandetanib

once daily oral dose

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Navelbine® ZD6474 ZACTIMA™

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with mesothelioma
* Previously treated with only one course of chemotherapy for mesothelioma
* No previous treatment with vinorelbine
* No serious heart problems within the last 3 months

Exclusion Criteria

* Serious abnormal laboratory values
* Severe or uncontrolled disease or condition as judged by the Investigator
* Pregnant or breast-feeding women
* Other cancers within the last 5 years
* Major surgery or radiation therapy within 4 weeks prior to starting study therapy
* Receipt of any investigational agents within 30 days prior to commencing study treatment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No